EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Eur J Cardiothorac Surg 2009;35:1091-1093. doi:10.1016/j.ejcts.2009.01.042
Copyright © 2009, European Association for Cardio-thoracic Surgery. Published by Elsevier. All rights reserved.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Anna L. Meyer
Martin Strüber
Right arrow Permission Requests
Google Scholar
Right arrow Articles by Malehsa, D.
Right arrow Articles by Strüber, M.
PubMed
Right arrow Articles by Malehsa, D.
Right arrow Articles by Strüber, M.
Related Collections
Right arrow Mechanical Circulatory Assistance


Case reports

Acquired von Willebrand syndrome after exchange of the HeartMate XVE to the HeartMate II ventricular assist device

Doris Malehsa, Anna L. Meyer, Christoph Bara, Martin Strüber*

Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany

Received 7 October 2008; received in revised form 29 January 2009; accepted 29 January 2009.

* Corresponding author. Tel.: +49 511 532 3435; fax: +49 511 532 8452. (Email: strueber.martin{at}mh-hannover.de).

Instead of pulsatile ventricular assist devices an increasing number of nonpulsatile ventricular assist devices are introduced to clinical practice. The different flow characteristics of this new technique lead to alteration in shear stress on blood components, which may affect the coagulation system. Repeated von Willebrand factor analyses were performed in a patient who first was implanted with a pulsatile ventricular assist device (Thoratec HeartMate XVE), which had to be replaced after 405 days with an axial flow device (HeartMate II). During support with the pulsatile ventricular assist device there was no sign of any coagulation disorder. However, on the axial flow device acquired von Willebrand syndrome Type 2 developed. Inhibition of platelet function was also observed, which may be in part due to the von Willebrand syndrome. The HeartMate II axial flow device may induce von Willebrand syndrome, which was not observed in HeartMate XVE pulsatile ventricular assist device. Patients put on continuous flow devices should be screened for acquired von Willebrand syndrome.

Key Words: Platelets • Von Willebrand syndrome • Ventricular assist device







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.